A lot of news on the research front in July, which can only be good. It’s a joy, relief as well as hope that one of those research projects or trials might lead to longer periods of remission, and perhaps a return to lesser disability for those with primary and secondary forms of multiple sclerosis. So let’s keep fingers, toes, eye lashes and anything else crossed that can be crossed. A lot of people with severe MS deserve at least that. Remember, 2.3 million people with MS globally is staggering. It doesn’t have to be that way, though. Research results Human Stem Cells Effectively Treat Multiple Sclerosis in Mice Models HCPLive – Embryonic stem cells are a potentially viable treatment option for multiple sclerosis (MS), according to research published online…

Research results Fatigue in Multiple Sclerosis Linked to Regional Brain Damage Multiple Sclerosis News Today – Fatigue, a common symptom of multiple sclerosis, could be a result of regional damage in the brain. Multiple sclerosis Reactivation of Epstein–Barr or herpes viruses not associated with MS relapse Nature.com – Infection with the Epstein–Barr virus or human herpesvirus 6 is associated with the initial onset of multiple sclerosis (MS) SLU researchers see possible answer to chemo pain in a multiple sclerosis drug Science Codex – A medication called FTY720 (Gilenya) is FDA-approved as a therapy for multiple sclerosis. Researchers publish one of the longest longitudinal studies of cognition in multiple sclerosis Medical Xpress – The article, “Cognitive impairment in multiple sclerosis: An 18-year follow-up study,” was epublished by Multiple Sclerosis and Related…

With a 14-day delay in posting some positive news about MS, I’d like to offer my apologies and no, I absolutely haven’t forgotten about you. As many people with MS know, May is about the busiest month for those who advocate and volunteer. World MS Day is the main day of the year for MSers, but before and after… sigh… there’s a lot to be said, done and needless to say… lots of sleep to be had. So without further ado, here is some news that might make your lips curl and your mind coo!

Research results Enhanced uptake of multiple sclerosis-derived myelin by THP-1 macrophages and primary human … 7thSpace Interactive (press release) – The pathological hallmark of multiple sclerosis (MS) is myelin phagocytosis. It remains unclear why microglia and macrophages demyelinate axons in … Textured insoles could be a positive step for people with MS UQ News – University of Queensland research is investigating the effects textured shoe insoles have on walking problems associated with multiple sclerosis. ANP reports positive results from chronic toxicity study of ATL1102 in multiple sclerosis News-Medical.net – Antisense Therapeutics Limited (“ANP” or the “Company”) is pleased to advise that results from a chronic toxicity study in monkeys indicate that …

A little bit later than usual, for which I apologise, but here is the good news that graced global media in March 2014.

Primary Progressive, Relapse-Free Secondary Progressive Multiple … BioNews Texas – secondary progressive multiple sclerosis nerve While there have been a number of success stories for MS research in 2013, last year saw yet another … Gov candidates cool to more marijuana legalization Kansas City Star – Most Republicans said it was too early to decide, but a Republican candidate for lieutenant governor who suffers from multiple sclerosis said it should …

With a bit of a delay, here is the good news in MS-world that found its way to the media in December 2013! Provincial MS strategy applauded Announced Nov. 25, Health Minister Fred Horne said the strategy – The Way Forward – “connects the dots” in the health care system so that Alberta’s almost 14,000 multiple sclerosis (MS) patients can access resources and find supports more easily. Teva and Takeda Announce Agreement for Glatiramer Acetate for Multiple Sclerosis Treatment in Japan Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Takeda Pharmaceutical Company Limited (Takeda) today announced the signing earlier this year of an agreement in which Teva licensed to Takeda the right to commercialize Teva’s innovative glatiramer acetate (active ingredient) formulation for the treatment of multiple sclerosis, in Japan. Teva and Takeda…